Companies › Cartesian Therapeutics
1 active drug program in 5 registered trials: 3 Phase 2, 1 Phase 3, 1 Phase 1; Neurology, Immunology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Descartes-08 Autologous T-cells expressing chimeric antigen receptor directed to BCMA | – | Phase 3 | Myasthaenia Gravis; Myasthenia Gravis, Generalized; Systemic Lupus Erythematosus (SLE); Antisynthetase Syndrome … | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04146051 | Descartes-08 | Phase 2 | Myasthenia Gravis, Generalized | Neurology | Jan 2026 |
| NCT06038474 | Descartes-08 | Phase 2 | Systemic Lupus Erythematosus (SLE) | Immunology | Dec 2026 |
| NCT06799247 | Descartes-08 | Phase 3 | Myasthaenia Gravis | Neurology | Dec 2026 |
| NCT07391605 | Descartes-08 | Phase 2 | Antisynthetase Syndrome | Other | Nov 2027 |
| NCT07089121 | Descartes-08 | Phase 1 | Childhood-onset Systemic Lupus Erythematous | Immunology | Dec 2027 |
Cash of $123m on 2026-09-30; operating cash outflow about $95m a year; runway about 16 months at that burn, to Jan 2028; 3 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Laboratorios Silanes S.A. de C.V. COMPASS Pathways NervGen Pharma Alumis Immunic
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.